ASANZHANOVA
Nurika Narynbekovna
PhD in Medicine, Head of Laboratory
Specialist in virology, biotechnology, vaccinology, and epidemiology. She has authored and co-authored over 100 scientific publications, including 57 articles (18 with non-zero impact factor in Web of Science and Scopus databases). She has contributed to the development of 9 veterinary vaccines and 6 human health vaccines and is a co-author of 5 national patents, 2 Eurasian patents, and 5 regulatory documents (NTD) on vaccines.
Awarded the “Science Leader — 2018” prize in the category “Most Cited Young Scientist of Kazakhstan 2008–2015” in the field of agricultural sciences. Recipient of the “Halyk Alghysy” medal in 2020 and the “Qurmet” order in 2021.
Training:
- 2024 – Certification course on “Biosafety, Epidemiology, and Microbiology of Infectious Diseases of Risk Group II,” NNCERI, Almaty, Kazakhstan.
- 2023 – Introductory course on development and production of biological products, IVI Global Training Hub for Biomanufacturing (GTH-B) supported by WHO, Seoul, South Korea.
- 2021 – Introductory GMP course, including Annex 1 “Manufacture of Sterile Medicinal Products,” UkrMedCert, Kazakhstan.
ORCID ID – https://orcid.org/0000-0001-7267-3931
Scopus ID – 55489464700
Web of Science ID – N-7976-2015
n.assanzhanova@biosafety.kz
+7(72636)7-22-28, вн. 133
Projects:
| AP05130505
|
Innovative Live Attenuated Cold-Adapted Viral Vaccine Against Equine Influenza: Investigation of new properties, production testing, and preparation for implementation and commercialization in Kazakhstan. |
| АР05131463
|
Development of a New Vector-Based Human Anti-Brucellosis Vaccine. |
|
BR06249226 |
Veterinary Safety of the Territory of the Republic of Kazakhstan: Epizootological monitoring, testing, implementation, and commercialization of specific prophylactic and diagnostic tools for particularly dangerous infectious diseases. |
Research areas of the laboratory:
- Development of technologies for the production of immunobiological preparations against socially significant infections of humans, animals, and birds.
- Isolation and study of viruses with biotechnological value.
- Experimental, pilot-industrial, and industrial production of vaccines and other medicinal products.
- Implementation of vaccine preparations and medicinal products in production.
Innovative developments of the laboratory:
The laboratory has developed innovative vaccines for both veterinary and human health:
Veterinary vaccines:
- Vector-based vaccine against bovine brucellosis.
- Live cold-adapted vaccine against equine influenza.
- Inactivated emulsified vaccines against avian influenza (mono- and bivalent).
- Inactivated and live vaccines against Newcastle disease, infectious laryngotracheitis, fowlpox, and other avian infections.
Human vaccines:
- Refluvac – inactivated whole-virion adjuvanted vaccine against pandemic influenza A/H1N1pdm09.
- Kazfluvac – inactivated whole-virion adjuvanted vaccine against pandemic influenza A/H5N1.
- Inactivated split vaccines (centrifugal and chromatographic) against seasonal influenza.
- Vector-based human anti-brucellosis vaccine.
Some of these developments have already been implemented and are widely used in practice, while others are in the process of production implementation.
Innovative developments of the laboratory: